Minerva Announces Amended Agreement for MIN-202 in Insomnia
31 mai 2017 16h05 HE
|
Minerva Neurosciences, Inc.
Minerva to gain global strategic control over development of MIN-202 for insomnia Janssen cash payments to Minerva of up to $70 million, including $30 million upfront All shares in Minerva held by...